Search research articles
Contact Us
Filters
Showing results (201-210 of 225) with videos related to
Page
of 23
Sort By:
The Lancet. Infectious Diseases
|
August 8, 2015
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
Angela Huttner, Julie-Anne Dayer, Sabine Yerly, et al.
Advances in Therapy
|
December 16, 2024
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals
Christoph D Spinner, Samira Bell, Hermann Einsele, et al.
Annals of the Rheumatic Diseases
|
March 18, 2016
Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative
Athan Baillet, Laure Gossec, Loreto Carmona, et al.
Annals of the Rheumatic Diseases
|
August 7, 2021
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis
Kulveer Mankia, Heidi J Siddle, Andreas Kerschbaumer, et al.
Joint Bone Spine
|
December 2, 2023
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies
Kim Lauper, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases
|
September 13, 2022
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries
Manuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, et al.
Annals of the Rheumatic Diseases
|
April 25, 2020
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Marie Kostine, Axel Finckh, Clifton O Bingham, et al.
Rheumatology (Oxford, England)
|
August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
Delphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 15, 2025
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
Romain Aymon, Denis Mongin, Romain Guemara, et al.
Annals of the Rheumatic Diseases
|
April 26, 2025
EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update
Linda Rüegg, Andrea Pluma, Sabrina Hamroun, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 225) with videos related to
Sort By:
Page
of 23
The Lancet. Infectious Diseases
|
August 8, 2015
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
Angela Huttner, Julie-Anne Dayer, Sabine Yerly, et al.
Advances in Therapy
|
December 16, 2024
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals
Christoph D Spinner, Samira Bell, Hermann Einsele, et al.
Annals of the Rheumatic Diseases
|
March 18, 2016
Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative
Athan Baillet, Laure Gossec, Loreto Carmona, et al.
Annals of the Rheumatic Diseases
|
August 7, 2021
EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis
Kulveer Mankia, Heidi J Siddle, Andreas Kerschbaumer, et al.
Joint Bone Spine
|
December 2, 2023
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies
Kim Lauper, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases
|
September 13, 2022
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries
Manuel Pombo-Suarez, Carlos Sanchez-Piedra, Juan Gómez-Reino, et al.
Annals of the Rheumatic Diseases
|
April 25, 2020
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Marie Kostine, Axel Finckh, Clifton O Bingham, et al.
Rheumatology (Oxford, England)
|
August 19, 2020
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
Delphine S Courvoisier, Katarina Chatzidionysiou, Denis Mongin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 15, 2025
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
Romain Aymon, Denis Mongin, Romain Guemara, et al.
Annals of the Rheumatic Diseases
|
April 26, 2025
EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update
Linda Rüegg, Andrea Pluma, Sabrina Hamroun, et al.
Page
of 23